Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland

Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland

Background Multiple biologic and targeted synthetic disease-modifying rheumatic drugs (b/tsDMARDs) are approved for the management of rheumatoid arthritis (RA), including TNF inhibitors (TNFi), bDMARDs with other modes of action (bDMARD-OMA) and Janus kinase inhibitors (JAKi). Combination of b/tsDMA...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: D Kyburz, C Gabay, A Finckh, C Tellenbach, L Herzog, A Scherer, B Moeller, A Ciurea, I von Muehlenen, L Brulhart, R Müller, P Hasler, P Zufferey
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: BMJ Publishing Group 2020-02-01
Sarja:RMD Open
Linkit:https://rmdopen.bmj.com/content/6/1/e001174.full

Internet

https://rmdopen.bmj.com/content/6/1/e001174.full

Samankaltaisia teoksia